Todd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance. He served in global leadership roles at ZELTIQ Aesthetics prior to the company’s acquisition by Allergan; at Galderma Laboratories, where he was President and General Manager of North America; and at Alcon Laboratories. He is a member of the board of directors of the Children’s Skin Disease Foundation.

Philip Brown brings over 25 years of clinical development experience to the Dermavant team. Prior to joining Dermavant in January 2019, Dr. Brown served as Head of Global Pharmaceutical Development at Galderma, as well as Senior Vice President of Clinical Development at Lexicon Pharmaceuticals, a publicly traded biopharmaceutical company. Dr. Brown received his MD from Texas Tech University Health Sciences Center School of Medicine, his JD from the University of Texas School of Law, and his BA from Hendrix College.

A member of the Dermavant team since early 2020, Chris Chapman brings 20 years of industry experience to his role. After receiving his BS from Towson University, Mr. Chapman spent 20 years in commercial roles, including: leading Pfizer’s U.S. Pharmaceutical Contracting and Pricing Organization division, as well as serving as the Vice President and General Manager of U.S. Prescription Business for Galderma, Senior Principal of the Core Access Group, and Executive Director for Managed Markets and Contracting for Medicis Pharmaceutical Corporation.

Following a distinguished career in academia as University of North Carolina Chapel Hill’s Louis C. Skinner Jr. Distinguished Professor of Dermatology, and years of experience in the pharmaceutical industry, David Rubenstein joined Dermavant in 2018 from GlaxoSmithKline Dermatology. During his time at GSK, he built an industry-leading dermatology drug development organization as Vice President, Discovery and Preclinical Development. Dr. Rubenstein received his BA in molecular biology from Princeton University and his MD and PhD from Duke University School of Medicine.

Chris Van Tuyl joined Dermavant in March 2018 and has over 20 years of legal experience. Prior to joining Dermavant, he was a corporate partner at the firm Sacks Tierney P.A., where his practices focused on the healthcare, pharmaceutical, and technology industries. He previously served in various in-house legal positions at publicly traded companies, including as Legal Executive at FIS Global; Corporate Secretary and Chief Compliance Officer at Rayonier Inc; and Associate General Counsel at Medicis Pharmaceutical Corporation. Mr. Van Tuyl began his legal career in private practice as a corporate attorney at the international law firms of Squire, Sanders & Dempsey LLP in Phoenix and Clifford Chance LLP in New York. He received his BS in finance summa cum laude from Arizona State University and his JD from Duke University School of Law.

Michael Swartzburg has over 20 years of leadership experience and finance expertise within the biotechnology and healthcare space. Prior to joining Dermavant, Mr. Swartzburg most recently served as Vice President of Finance and in Principal Financial and Accounting Officer roles at Iovance Biotherapeutics, where he participated in over $1 billion in equity raises. Before Iovance, Mr. Swartzburg provided CFO and board advisory services at various biotech companies and served as Vice President of Finance, Controller and Principal Accounting Officer at Adverum Biotechnologies, where he was part of the team that steered Adverum through their successful IPO. He began his career as a Certified Public Accountant and auditor at Ernst & Young in Los Angeles.

Paul Seaback brings 30 years of technical operations and CMC global leadership in biopharmaceuticals from clinical and commercial companies to his role as Chief Technical Officer. Prior to joining Dermavant in May 2018, Mr. Seaback held leadership roles as VP of Operations and Supply at IGNYTA, Head of Global Supply at Gilead Sciences, and VP of Manufacturing and Global Supply Chain at Medicis Pharmaceutical, as well as additional leadership roles at Hospira, Mayne Pharma, Cardinal Health, and Novartis.